Innovation at the Right Time, Setting Sail Anew: 2022 MGI & IDG Capital Life Health Accelerator Officially Launched

On August 12, the 2022 MGI & IDG Capital Life Health Accelerator Camp (hereinafter referred to as the “Accelerator Camp”), co-hosted by MGI Tech, IDG Capital Innovation Investment Research Institute, and Blue Rainbow Life Sciences Accelerator, was launched at the Shenzhen Qianhai Shenzhen-Hong Kong Youth Dream Factory. At the opening ceremony, eight projects participating in the Accelerator Camp made their debut. Government agencies, leading industry enterprises, sci-tech innovation companies, investment institutions, and universities and research institutes were invited to attend the event. Through a series of thematic sharing sessions, core courses, and diverse main venue activities, participants engaged in in-depth interactive exchanges, promoting resource flow and deep empowerment within the Accelerator Camp’s open innovation ecosystem.

Innovation at the Right Time, Setting Sail on a New Journey. The Accelerator Camp continues to leverage its advantages in aggregating industry, capital, and technology, unlocking potential, stimulating vitality, and injecting greater innovative momentum into enterprises. This year, the organizers remained firmly focused on frontier innovative technologies in the life sciences sector. After several months of project recruitment, online seminars, and rigorous selection, eight final cohort projects and eight reserve projects emerged as standouts. These projects span fields including gene therapy, innovative vaccines, clinical applications of single-cell sequencing, microbial detection, spatial omics, proteomics, AI-enabled synthetic biology, and brain science, thereby infusing the Accelerator Camp with a vital “source of fresh water” for innovation.

As one of the organizers of the accelerator program, Liu Bo, CFO of MGI Tech, welcomed the attending guests at the opening of the event and introduced MGI Tech’s original vision and steadfast commitment to building an innovative ecosystem for the life and health industry. Mr. Liu noted that startups in the new economy face numerous challenges. Seizing this opportunity, MGI Tech, as an upstream enterprise in the life sciences sector, aims to leverage its platform advantages to collaborate with partners such as IDG Capital Innovation Investment Research Institute and Blue Rainbow. Together, they provide comprehensive incubation support—including resources, capital, and technology—to projects participating in the accelerator program, thereby contributing to the industrial development of the life sciences field. Over the five years of collaboration between MGI Tech and the accelerator program, both parties have shared resources and worked closely together, successfully driving many life science startups to accelerate their innovation and upgrading. This year, the accelerator program has further upgraded its offerings by providing an “Innovation Toolkit,” which includes sequencing reagents, single-cell library preparation kits, customized smart laboratory management systems, and consulting services for laboratory automation design and construction. Participating projects have the opportunity to receive an Innovation Toolkit valued at up to RMB 1 million, aimed at facilitating the industrial translation of R&D achievements.

Fu Wenbo, General Manager of IDG Capital’s Innovation Investment Research Institute, addressed the attendees onlineBeltIn his address, he noted that IDG Capital has long focused on the life sciences sector, making sustained investments in basic scientific research and cutting-edge technologies. Through its systematic strategic investment layout, IDG Capital has established a global innovation and entrepreneurship ecosystem network. The IDG Capital Innovation Investment Research Institute, initiated by IDG Capital, leverages its unique innovation ecosystem resources to provide startups with commercialization empowerment from a capital perspective. Meanwhile, we also hope that along the challenging entrepreneurial journey, the participating projects will work hand in hand and move forward together under the guidance and support of the accelerator program.

Zhao Weiwen, CEO of the Blue Rainbow Life Sciences Accelerator and Managing Partner of Miracle Light Venture Capital Fund, shared the accelerator’s innovative incubation model and its achievements. In the face of rapid technological advancements and the uncertainties and challenges posed by the industry environment, Blue Rainbow Life Sciences Accelerator has consistently positioned itself as a sci-tech service provider, an innovation incubator, and an industry connector. It is committed to streamlining the entire acceleration chain for startups—from basic research to product development and commercialization—providing comprehensive incubation services encompassing all essential innovation elements. This year marks the fifth anniversary of the Life Health Accelerator Camp hosted by Blue Rainbow. Leveraging its mature model and proven experience developed over years of exploration, Blue Rainbow has adopted a triple-drive approach integrating investment, incubation, and industry collaboration. This strategy has cultivated more than 200 high-level, interdisciplinary innovation and entrepreneurship talents in the life and health sectors, facilitated the rapid early-stage growth of nearly 50 life sciences startup projects, and achieved a cumulative project valuation exceeding RMB 10 billion.

Passing the Torch, Carrying Forward Hope. During the flag-handover ceremony, Peng Peng, representative of ZhiLing Bio—a star project from previous Accelerator Camps—raised the Accelerator Camp flag high and passed it to the participating projects of the current cohort, officially launching the 2022 MGI & IDG Capital Life Health Accelerator Camp.

During the themed sharing session, Wang Jingjing, Director of Product Marketing at MGI Tech, presented on empowering startups within leading healthcare institutions. The source of life lies in genes. As the core foundational tool for deciphering the genetic code, gene sequencers are integral to the entire life sciences industry. Ms. Wang highlighted that MGI Tech has always adhered to the philosophy of “Innovative Intelligent Manufacturing Leading Life Sciences,” striving to become a creator of core tools for life sciences. Through strategic top-level design and the support of multiple core technologies, MGI Tech has established three core business segments: the sequencer product line, the laboratory automation product line, and new business initiatives, thereby empowering development across more industries. Meanwhile, MGI Tech aims to play a supportive and safeguarding role in the development of the life sciences industry, continuously collaborating with various sectors for innovation and open cooperation, and providing comprehensive empowerment to startups.

At a global healthcare investment and financing sharing session, IDG Capital stated that compared to the first half of the year, the number of early-stage investments in the healthcare sector has further increased, mainly concentrated in three major areas: innovative drugs, MedTech, and healthcare services, indicating that capital interest in startups remains strong. Meanwhile, signals of easing "herd behavior" in funding suggest a dispersal of competitive trends in niche sectors, which is conducive to valuation reassessment and the healthy development of the industry.

Meanwhile, the inaugural core entrepreneurship course officially commenced. Four entrepreneurship mentors guided founders through strategic layout and focused “point” thinking within the “Macro Trends and Financing Strategy” module. Treating the business world as a “battlefield,” Zhao Weiwen, Executive President of Blue Rainbow Life Sciences Accelerator and Managing Partner of Miracle Light Venture Capital Fund, kicked off the core entrepreneurship curriculum with a lecture titled “Entrepreneurship 101: The Simplest Things in Entrepreneurship.” Drawing on the philosophical framework of “Moral Law, Heaven, Earth, Commander, and Method” from The Art of War, Mr. Zhao provided an in-depth analysis of the five key factors influencing success in startup strategic planning. By applying ancient military strategy to modern startup operations and integrating multiple real-world case studies, he comprehensively elucidated the critical determinants of entrepreneurial success or failure.Mao Jingyi, Head of Compliance and Chair of the Supervisory Board at Yuce Bio, delivered a session titled “The Way to Open Sources: Planning and Selecting Funding Channels for Startups.” Addressing the ever-changing capital markets, Ms. Mao compared the characteristics of different financing models and offered funding planning recommendations, helping entrepreneurs select appropriate financing instruments based on their specific development stages.Hu Mingyi, Partner at Mingde Capital, presented “Seamless Integration: Tailoring the ‘Ideal’ Business Plan and Pitch.” Adopting an investor’s perspective and engaging in interactive discussions with participants, Mr. Hu clarified the core highlights, business logic, market size, and other key aspects that investors focus on in business plans (BPs). His session provided entrepreneurs with fresh inspiration and approaches for drafting BPs, along with practical tips for delivering outstanding project pitches. In another session, “Strategic Offense and Defense: Core Essentials of Financing Term Negotiations,” Mr. Hu drew on his extensive experience in the financing advisory industry to provide detailed analyses of key terms and common points of contention throughout the financing process, offering valuable advice on investment term negotiations for both entrepreneurs and investors.Dai Minghan, Investment Director at Miracle Light Venture Capital Fund, explained methods for conducting background research on investors and effective communication techniques. Her guidance helped entrepreneurs identify the key evaluation criteria prioritized by investors, thereby facilitating the establishment of strong, trust-based relationships with them.

During the event, the Accelerator Camp specially organized team-building and icebreaker activities. Through self-introductions, interactive games, and frisbee matches, participants engaged in in-depth exchanges, shared lessons learned from past pitfalls, and fostered unity and collaboration while strengthening community bonds. In the subsequent phase of the Accelerator Camp, a series of core entrepreneurship courses covering various modules and diverse flagship events will be rolled out. Additionally, this year’s Accelerator Camp introduces a new POC (Proof of Concept) Workshop to provide entrepreneurs with professional guidance and advice. Stay tuned.

Program Overview

Project 1:

The project is dedicated to leveraging cutting-edge immunological technologies to provide screening and treatment solutions for pediatric diseases. Focusing on childhood disorders, it investigates the genetic and immune mechanisms underlying disease onset, progression, and outcomes, while developing early screening tools, companion diagnostics, and biomarker-based precision therapy regimens.

Project 2:

The company is a biotechnology firm leveraging an AI data-driven and synthetic biology innovation platform to develop next-generation adeno-associated virus (AAV) vectors for gene therapy. Through independent R&D and strategic collaborations, it is committed to advancing more high-value gene therapy pipelines into clinical stages and ultimately to commercialization.

Project 3:

The project is dedicated to the clinical translation of single-cell technologies, focusing on three core platforms: single-cell enrichment and detection, single-cell sequencing, and AI-driven single-cell data analysis. It has established unique analytical workflows and methodologies for single-cell transcriptomics, spatial transcriptomics, and integrated single-cell and bulk multi-omics analyses. To date, the project has accumulated hundreds of single-cell analysis methods and a single-cell database containing millions of cells.

Project 4:

The project is dedicated to the research and development of internationally leading analytical and detection technologies. It features high-throughput, multi-parametric single-exosome detection technology, complemented by a bioinformatics analysis pipeline for deciphering single-exosome fingerprint characteristics. This establishes an efficient platform for “exploring every exosome,” accelerating the research and development of exosome-based disease screening and diagnostics.

Project 5:

The project features an "innovative VLP vaccine foundational technology platform," offering industrialization advantages such as modular design, ease of scalable manufacturing, and strong expandability, as well as technical advantages including high immunogenicity, superior safety, and long-lasting protection. It focuses on major vaccine candidates in the respiratory and non-respiratory categories that are "Me-better" and "First-in-class."

Project 6:

Centering on brain health challenges such as sleep disorders, the project is dedicated to developing innovative neuromodulation therapies for neurological diseases and advancing the domestic R&D of modulation devices. It strives to become a 24/7 brain health expert spanning from clinical settings to home care, working tirelessly toward the vision of “Stronger Brains, Brighter Futures.”

Project 7:

Leveraging the robust scientific research capabilities of BGI Research in Shenzhen and the channel influence of BGI Group in the healthcare sector, this project focuses on the research, development, and application of gene delivery vectors and gene modification technologies, with a commitment to treating hemoglobin disorders.

Project 8:

The project focuses on precision diagnostics for pathogenic microorganisms, has repeatedly passed the microbial quality assessments conducted by the National Clinical Laboratory Center, and was designated as one of the first batch of COVID-19 testing institutions by the Nanjing Municipal Health Commission. Adopting a development model that integrates services with products, its service business covers more than 200 hospitals across China.